 |
The Journal of Neuroscience, September 3, 2003, 23(22):8029-8033
Previous Article | Next Article 
BRIEF COMMUNICATION
Molecular-Imaging Probe 2-(1-{6-[(2-Fluoroethyl)(Methyl) Amino]-2-Naphthyl}Ethylidene) Malononitrile Labels Prion Plaques In Vitro
Mara Bresjanac,1,2
Lojze M. Smid,1,2
Tomaz D. Vovko,1,2
Andrej Petri ,3
Jorge R. Barrio,4 and
Mara Popovic2
1Laboratory for Neuronal Plasticity and
Regeneration, Institute of Pathophysiology, 2Prion
Laboratory, Institute of Pathology, School of Medicine, and
3Faculty of Chemistry and Chemical Technology,
University of Ljubljana, SI-1000 Ljubljana, Slovenia, and
4Division of Nuclear Medicine, Department of Molecular
and Medical Pharmacology, Laboratory of Structural Biology and Molecular
Medicine, University of California, Los Angeles, School of Medicine, Los
Angeles, California 90095
The study aimed to evaluate the fluorescent molecular-imaging probe
2-(1-{6-[(2-fluoroethyl)(methyl)amino]-2-naphthyl}ethylidene)malononitrile
(FDDNP) for its ability to selectively and reproducibly label prion plaques in
fixed, paraffin-embedded cerebellar sections from patients of confirmed
Gerstmann-Sträussler-Scheinker disease, sporadic Creutzfeldt-Jacob
disease (CJD) with kuru plaques, and variant CJD (vCJD). FDDNP is a highly
hydrophobic, viscosity-sensitive, solvent-sensitive, fluorescent substance,
whose radiofluorinated analog [18F]FDDNP has recently been
successfully used to label senile plaques and neurofibrillary tangles in the
living brain of Alzheimer's disease patients with positron emission
tomography. Our results show that FDDNP reliably identifies all prion plaques,
including small cluster-plaques in vCJD. This finding may open new in
vivo diagnostic possibilities for vCJD.
Key words: fluorescent labeling; human; neuroimaging; TSE; variant Creutzfeldt-Jacob disease; amyloid
Received April 8, 2003;
revised May 27, 2003;
accepted July 14, 2003.
This article has been cited by other articles:

|
 |

|
 |
 
Y. Kawasaki, K. Kawagoe, C.-j. Chen, K. Teruya, Y. Sakasegawa, and K. Doh-ura
Orally Administered Amyloidophilic Compound Is Effective in Prolonging the Incubation Periods of Animals Cerebrally Infected with Prion Diseases in a Prion Strain-Dependent Manner
J. Virol.,
December 1, 2007;
81(23):
12889 - 12898.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. L. Boxer, G. D. Rabinovici, V. Kepe, J. Goldman, A. J. Furst, S. -C. Huang, S. L. Baker, J. P. O'Neil, H. Chui, M. D. Geschwind, et al.
Amyloid imaging in distinguishing atypical prion disease from Alzheimer disease
Neurology,
July 17, 2007;
69(3):
283 - 290.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R G Macfarlane, S J Wroe, J Collinge, T A Yousry, and H R Jager
Neuroimaging findings in human prion disease
J. Neurol. Neurosurg. Psychiatry,
July 1, 2007;
78(7):
664 - 670.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|

|